IKKb inhibition is an interesting approach to tackle a number of diseases where there is currently signifcant unmet medical needs. Opal Oncology is using creative approaches to design, prepare and evaluate novel compounds with attractive biological, physicochemical, pharmacokinetic and safety profiles. Preferred compounds will subsequently be progressed into in vivo disease model evaluation alongside GLP toxicity and safety pharmacology evaluation as a precursor to candidate selection and help prioritise clinical evaluation plans to select appropriate disease indications.